TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04495946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sepsis Transition and Recovery (STAR) program
Description: In the STAR program intervention, a centrally located nurse navigator facilitates the application of four evidence-based core components of post-sepsis care (i.e., review of medications, new impairments, comorbidities, and palliative care) to patients prior to and during the 90 days after hospital discharge. The STAR navigator will provide telephone and EHR-based support within the hospitalization and to patients across all discharge settings with remote monitoring at specified intervals following hospital discharge. Patients will continue to receive STAR directed services for 90 days following their discharge and then will be transitioned back to the next appropriate care location.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Hospitals and their patients will not have access to the STAR program. Patients will continue to receive usual care throughout their stay and discharge, consisting of: patient education and follow-up instructions at discharge, which are not specific to sepsis; routine recommendations for follow-up visits with primary care providers; arrangements for home health services or care management follow-up based on each patient's needs but not specifically tailored to the sepsis population; discharge to post-acute setting with no sepsis-specific follow-up. All aspects of usual care will be determined by treating clinicians independent of trial assignment.
Study: NCT02714491

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erigo + Music
Description: The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks) and musical stimulation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erigo + Metronome
Description: The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks) and metronome stimulation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erigo + Silence
Description: The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks), without auditory stimulation.
Study: NCT01354613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Participants will be randomized to treatment with either amlodipine 5 mg daily or placebo, in double-blind fashion, 25 patients in each group. 12 week oral administration of 5mg/day, uptitrated to 10mg/day, determined by PI.
Study: NCT00357149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapy
Study: NCT01466491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracervical block technique with lidocaine
Description: The PCB will consist of a total of 20 mL local anesthetic (18 mL of 1% lidocaine buffered with 2 mL sodium bicarbonate) injected with the following technique: 2 mL are injected at the tenaculum site, 12 o'clock, superficially into the cervix. The tenaculum is placed at 12 o'clock. The remaining 18 mL are injected paracervically (vaginal fornices) over sixty seconds. The injection, occurring in either two or four sites, is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal). It will be followed with either no wait or a three-minute wait period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracervical block technique with lidocaine
Description: The PCB will consist of a total of 20 mL local anesthetic (18 mL of 1% lidocaine buffered with 2 mL sodium bicarbonate) injected with the following technique: 2 mL are injected at the tenaculum site, 12 o'clock, superficially into the cervix. The tenaculum is placed at 12 o'clock. The remaining 18 mL are injected paracervically (vaginal fornices) over sixty seconds. The injection, occurring in either two or four sites, is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal). It will be followed with either no wait or a three-minute wait period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracervical block technique with lidocaine
Description: The PCB will consist of a total of 20 mL local anesthetic (18 mL of 1% lidocaine buffered with 2 mL sodium bicarbonate) injected with the following technique: 2 mL are injected at the tenaculum site, 12 o'clock, superficially into the cervix. The tenaculum is placed at 12 o'clock. The remaining 18 mL are injected paracervically (vaginal fornices) over sixty seconds. The injection, occurring in either two or four sites, is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal). It will be followed with either no wait or a three-minute wait period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracervical block technique with lidocaine
Description: The PCB will consist of a total of 20 mL local anesthetic (18 mL of 1% lidocaine buffered with 2 mL sodium bicarbonate) injected with the following technique: 2 mL are injected at the tenaculum site, 12 o'clock, superficially into the cervix. The tenaculum is placed at 12 o'clock. The remaining 18 mL are injected paracervically (vaginal fornices) over sixty seconds. The injection, occurring in either two or four sites, is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal). It will be followed with either no wait or a three-minute wait period.
Study: NCT03069040

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nerve sparing radical hysterectomy
Description: Type C1 radical hysterectomy,that is nerve sparing radical hysterectomy, requires separation of two parts of the dorsal parametria: the medialpart , which entails recto -uterineandrecto-vaginal ligaments, and the lateral laminar structure, also called mesoureter, which contains the hypogastric plexus. Furthermore, type C1 requires only a partial dissection of the ureter from the ventral parametria, which is usually asymmetric towards more extensive resection of the medial leaf of the cranial (above the ureter) part of the ventral parametria .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radical hysterectomy
Description: In the C2 type, the ureter is completely dissected from the ventral parametria up to the urinary bladder wall. Defining the resection limits on the longitudinal (deep parametrial or vertical) plane is crucial for distinguishing between types C1 and C2.
Study: NCT03218280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Study: NCT03844087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiplanar neuromuscular training
Description: See arm description
Study: NCT02871817

Intervention type: OTHER
Intervention: Paxos Checkup Study Mobile Medical Application
Description: The Digisight Paxos Checkup TM is mobile vision assessment system which consists of an application installed on a mobile device with an Internet connection, an Internet Cloud-based vision care network and a web site. The Paxos Checkup app contains a set of quantitative near vision tests, which a patient can take at home or elsewhere using an Internet capable mobile device.

Intervention type: OTHER
Intervention: Paxos Checkup Study Mobile Medical Application
Description: The Digisight Paxos Checkup TM is mobile vision assessment system which consists of an application installed on a mobile device with an Internet connection, an Internet Cloud-based vision care network and a web site. The Paxos Checkup app contains a set of quantitative near vision tests, which a patient can take at home or elsewhere using an Internet capable mobile device.
Study: NCT00357149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant cisplatin, 5-FU and radiotherapy
Study: NCT02871817

Intervention type: OTHER
Intervention: Paxos Checkup Study Mobile Medical Application
Description: The Digisight Paxos Checkup TM is mobile vision assessment system which consists of an application installed on a mobile device with an Internet connection, an Internet Cloud-based vision care network and a web site. The Paxos Checkup app contains a set of quantitative near vision tests, which a patient can take at home or elsewhere using an Internet capable mobile device.
Study: NCT04244240

Intervention type: BEHAVIORAL
Intervention: BEARNI Tool
Description: BEARNI is brief screening tool initially validated for Alcohol-related neuropsychological impairments (Ritz et al., 2015). BEARNI tool detect impairment in visuospatial abilities, executive functions, verbal episodic memory, and verbal working memory.~The score of the test could be expressed as a global score, and also as subscores corresponding to each cognitive subtest. Normative data are available.
Study: NCT01340222

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: biological samples
Description: 4 blood sampling will be made at J0, J2, J4, J6 befor delivery and 1 blood sampling 3 days after delivery

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: biological samples
Description: 4 blood sampling will be made at J0, J2, J4, J6 befor delivery and 1 blood sampling 3 days after delivery
Study: NCT04195490

Intervention type: PROCEDURE
Group type: OTHER
Intervention: feminizing genitoplasty
Description: feminizing genitoplasty including vaginoplasty,clitroplasty, labioplasty and urethroplasty
Study: NCT00876863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CERE-110: Adeno-Associated Virus injection Surgery
Description: Injecting CERE-110 2.0 X 10\^11 vg into brain during surgical procedure.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Placebo Surgery
Description: Placebo Surgery
Study: NCT06239883

Intervention type: OTHER
Intervention: Voiding diary
Description: The patients with diagnosed OSA will be asked to fill in the voiding diary.
Study: NCT01747915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin Dose Level 1
Description: Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 300 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum dose of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin Dose Level 2
Description: Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 600 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, either liquid or capsule, dosed twice daily beginning at Randomization to End of Study/Early Termination.
Study: NCT00094926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperdal Consta
Description: 25, 37.5 or 50mg IM injections every 2wks for 52wks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo IM injections every 2wks for 52wks
Study: NCT00737724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simultaneous ARV and antiMTB
Description: Receives both, simultaneously antiretroviral therapy and antituberculosis therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferred RV and antiMTB treatment
Description: Receives only antituberculosis therapy and 2 months afterwards antiretroviral therapy
Study: NCT03907787

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Zingiber officinale and Acmella oleracea
Description: Subjects were supplied for four weeks with two tablets/day and there was the evaluation of pain intensity, by a 30-days Visual Analogue Scale (VAS) and b) the assessment of knee function by Western Ontario and McMaster Universities Arthritis Index and by Tegner Lysholm Knee Scoring collected at baseline, at 15 and 30 days after treatment, Health-related quality of life, by the ShortForm36, inflammation by C-reactive protein and Erythrocyte Sedimentation Rate, body composition by dual-energy X-ray absorptiometry measured at baseline and 30 days after treatment.
Study: NCT00454272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teicoplanin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Study: NCT04085146

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized optimal positive end-expiratory pressure
Description: Optimal PEEP will be determined by the automated procedure of step-wised decrease in the amount of PEEP of the anesthesia ventilator Aisys Care Station (GE Healthcare, Madison, Wisconsin, USA).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional positive end-expiratory pressure
Description: A same amount of PEEP of 7 centimeter hydrogen dioxide will be provided during the laparoscopic period of surgery.
Study: NCT01470131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib
Description: Masitinib 6 mg/kg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT01605773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repaglinide
Description: Dose individually adjusted and conducted according to labeling
Study: NCT03247517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200mg SPN-812
Description: 200mg SPN-812 was administered once daily and compared to placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400mg SPN-812
Description: 400mg SPN-812 was administered once daily and compared to placebo
Study: NCT02196701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Administered by subcutaneous injection every other week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate was provided as 2.5 mg tablets for oral administration.
Study: NCT01099527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)
Description: dose escalation of capecitabine, everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: dose escalation of capecitabine, everolimus
Study: NCT00894738

Intervention type: PROCEDURE
Intervention: Testing (MRS, US, DEXA, blood tests)
Description: Magnetic Resonance Spectroscopy (MRS) of the liver to determine hepatic triglyceride content; ultrasound (US) of the carotid artery to determine intima-media thickness; dual energy X-ray absorptiometry (DEXA) to determine body composition; fasting lipids, fasting insulin, C-reactive protein, liver enzymes and fibrinogen levels.

Intervention type: PROCEDURE
Intervention: Testing (MRS, US, DEXA, blood tests)
Description: Magnetic Resonance Spectroscopy (MRS) of the liver to determine hepatic triglyceride content; ultrasound (US) of the carotid artery to determine intima-media thickness; dual energy X-ray absorptiometry (DEXA) to determine body composition; fasting lipids, fasting insulin, C-reactive protein, liver enzymes and fibrinogen levels.
Study: NCT01470131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Standard therapy (cycles of bortezomib)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bortezomib
Description: Standard therapy (cycles of bortezomib)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Standard therapy (cycles of dexamethasone)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Standard therapy (cycles of dexamethasone)
Study: NCT03909412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered over 10 minutes for the 20 mg/m2 and 27 mg/m2 dose and over 30 minutes for all higher doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered over 10 minutes for the 20 mg/m2 and 27 mg/m2 dose and over 30 minutes for all higher doses.
Study: NCT01605773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glyburide
Description: Dose individually adjusted and conducted according to labeling
Study: NCT01316731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single legged exercise
Description: A single exercise bout that consists of one hour one-legged cycling on a adapted recumbent cycle ergometer at a submaximal rate. The non-exercising leg will serve as control for the exercising leg.
Study: NCT04911829

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Study: NCT04587596

Intervention type: OTHER
Intervention: Pain education
Description: 70 minute lecture about chronic pain and one focus group afterwards
Study: NCT03067194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 100 MG
Description: Celecoxib 100mg, Oral, BID(twice per day), During 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200mg
Description: Celecoxib 200mg, Oral, QD(once daily), During 6 weeks
Study: NCT00003828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Study: NCT03115788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat induced pain
Description: For the heat induced thermal pain, the research nurse will train the subject to estimate pain quantitatively using a 2 cm 2 Peltier controlled thermode (TSA®) applied to the skin of the arm. Typically, the subject is exposed to temperatures between 41° and 49° C using a random staircase method. After the volunteer learns to qualitatively estimate the thermal pain, pain will be established by heating the the leg with a 4 cm2 Peltier controlled thermode (TSA®) for 90 seconds with the probe clamped at a thermal intensity of 47°C.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Induced Pain
Description: Cold pain will be induced by placing a foot in a container of circulating water maintained at 10°C for 90 seconds (n=20). Half (n=20) of the subjects will have the foot placed in body temperature water of 38°C.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iPad

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPad
Study: NCT01154595

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plumpy Doz(r) - Ready-to-Use Food
Description: 47g Plumpy Doz(r) per day per child

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food-for-Training
Description: Conditional family food supplementation (sugar, sorghum, beans, iodized salt, vegetable oil) 1800 kcal/person/day in function of attendance and participation in a sensitization program covering various themes on household, water and disease management, hygiene promotion, sanitation and dietary practices for children.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food-for-Training
Description: Conditional family food supplementation (sugar, sorghum, beans, iodized salt, vegetable oil) 1800 kcal/person/day in function of attendance and participation in a sensitization program covering various themes on household, water and disease management, hygiene promotion, sanitation and dietary practices for children.
Study: NCT01167153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan/Amlodipine
Description: Valsartan/Amlodipine 80/5mg single pill combination (SPC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg
Study: NCT03194620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thearubigins
Description: Single oral intake of 94.9 mg of therubigins (isolated from black tea) in a flavanol-free, fruit flavored, non-dairy drink

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theaflavins
Description: Single oral intake of 120 µmol of an equimolar mixture of theaflavins (isolated from black tea) in a flavanol-free, fruit flavored, non-dairy drink. The theaflavin mix includes theaflavin, theaflavin-3-gallate and theaflavin-3,3'-gallate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procyanidin Dimer B2 (DB2)
Description: Single oral intake of 120 µmol of Procyanidin Dimer B2 (DB2) (isolated from Theobroma cacao) in a flavanol-free, fruit flavored, non-dairy drink.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: (-)-Epigallocatechin-3-O-gallate (EGCG)
Description: Single oral intake of 120 µmol of (-)-Epigallocatechin-3-O-gallate (EGCG)(isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: (-)-Epicatechin-3-O-gallate (ECG)
Description: Single oral intake of 120 µmol of (-)-Epicatechin-3-O-gallate (ECG) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: (-)-Epicatechin (EC)
Description: Single oral intake of 120 µmol of (-)-Epicatechin (EC) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: (-)-Epigallocatechin (EGC)
Description: Single oral intake of 120 µmol of (-)-Epigallocatechin (EGC) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Single oral intake of a flavanol-free, fruit flavored, non-dairy drink.
Study: NCT01566591

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep TMS Treatment
Description: 24 TMS treatments over 6 weeks .

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: 24 TMS treatments over 6 weeks
Study: NCT01433120

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei ssp paracasei F19
Description: 10\^10 CFU of Lactobacillus paracasei F19 (dissolved in a glass of water once per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flax seed fibres
Description: 10 grams of flax seed fibres per day (baked into two breakfast buns)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin (Placebo)
Description: Maltodextrin is dissolved in a glas of water once per day
Study: NCT04766983

Intervention type: DIAGNOSTIC_TEST
Intervention: bronchoalveolar lavage
Description: BAL and ETA are performed as per clinical practice on clinical suspicion of VAP (Johanson score)

Intervention type: DIAGNOSTIC_TEST
Intervention: bronchoalveolar lavage
Description: BAL and ETA are performed as per clinical practice on clinical suspicion of VAP (Johanson score)
Study: NCT03524911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHFFF nutrition education
Study: NCT01269047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide
Description: Start at 15 mcg capped at 60 mcg before breakfast and supper subcutaneously for 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Start at 1.25 mcg, capped at 5 mcg, subcutaneously, before breakfast and supper for 4 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Rapid acting and long acting, subcutaneously, according to their regimen for the entire duration of the study.